Form 4 holding
Chief Operating Officer
Monopar Therapeutics
- Security class
- Common Stock
- Shares / value
- 58,054
- Estimated value
- $5,375,219
- Report date
- 30 Sep 2026
- Price
- $92.59
- Ownership
- Direct
Andrew Cittadine - Chief Operating Officer at Monopar Therapeutics
Issuer-level insider activity
- Role
- Chief Operating Officer
- Issuer ticker
- MNPR on Nasdaq
- Entity type
- Individual
- Source filing history
- Open source filing history
Identity
Names, identifiers, and filing context for this profile.
1 identity field
Source evidence
Original filing metadata and source links for verification.
1 source field
No buys or sells have been reported by Andrew Cittadine since 06 Oct 2025
Reported holdings for Andrew Cittadine in Monopar Therapeutics
Form 4 holding
Chief Operating Officer
Monopar Therapeutics
- Security class
- Restricted Stock Units
- Shares / value
- 52,593
- Estimated value
- $1,136,410
- Report date
- 02 Dec 2025
- Price
- $22.00
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
Form 4 holding
Chief Operating Officer
Monopar Therapeutics
- Security class
- Restricted Stock Unit
- Shares / value
- 35,115
- Estimated value
- Report date
- 30 Sep 2026
- Price
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
Form 4 holding
Chief Operating Officer
Monopar Therapeutics
- Security class
- Stock Options
- Shares / value
- 8,969
- Estimated value
- Report date
- 02 Dec 2025
- Price
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
Transaction history for Andrew Cittadine in Monopar Therapeutics
| Sym | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares after | Date | Ownership |
|---|
* marks a reported price that did not pass the local price check.